



SPAFID CONNECT

Informazione Regolamentata n. 0472-23-2018	Data/Ora Ricezione 12 Luglio 2018 18:12:24	MTA - Star
--	--	------------

Societa' : BB BIOTECH

Identificativo : 106238

Informazione
Regolamentata

Nome utilizzatore : BIOTECHNSS01 - Alderuccio

Tipologia : 1.2

Data/Ora Ricezione : 12 Luglio 2018 18:12:24

Data/Ora Inizio : 12 Luglio 2018 18:12:25

Diffusione presunta

Oggetto : BB Biotech AG reports preliminary results
for 1H 2018

Testo del comunicato

Vedi allegato.

Media Release, July 12, 2018

BB Biotech AG reports preliminary results for 1H 2018

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for the first half year of 2018.

Based on preliminary unaudited consolidated results, BB Biotech closed the first half year of 2018 with a loss of around CHF 70 mn (CHF 478.4 mn profit in the corresponding period of the previous year). As an investment company, the result reflects the performance of the stocks it holds in its investment portfolio.

BB Biotech's share price increased 8.4% in CHF and 8.2% in EUR during the corresponding period.

The interim report as of June 30, 2018 will be published on July 20, 2018.

For further information:

Investor Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Dr. Silvia Schanz, ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch

Media Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 07
Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Fine Comunicato n.0472-23

Numero di Pagine: 3